Developer docs
API playgroundTry for free, no card

Search company profiles

Nalagenetics

Full company profile

uuid0002a2x

Namestring
Nalagenetics
Legal namestring
Nalagenetics Pte Ltd
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Nalagenetics is a Singapore-based genomics company founded in 2016 that develops genetic testing products and clinical decision support software, with a particular specialization in Southeast Asian population-specific algorithms. The company operates a dual business model spanning direct-to-consumer DNA test kits sold through its own e-commerce platform and NalaCare clinic (RxMax covering 240+ medications, RxReady covering 180+ medications, MammoReady for breast cancer risk, CardiacReady for cardiovascular risk, NutriReady for nutrition, LifeReady for lifestyle, plus prenatal and rare disease diagnostics) and a B2B enterprise platform called Nala CDS that delivers NGS data analysis, pharmacogenomics reporting, polygenic risk scoring, and combined genetics-plus-epigenetics risk assessment to hospitals, laboratories, and research institutions on cloud-based or on-premise deployment.

The underlying technology stack combines multiple genomic modalities — microarray, qPCR, whole-genome sequencing (WGS), whole-exome sequencing (WES), and optical genome mapping (OGM) — with proprietary AI-powered bioinformatics for pharmacogenomics interpretation, polygenic risk scoring across 10+ conditions, and ACMG-compliant rare disease pipelines. The platform holds ISO 13485, ISO 27001, HIPAA, Singapore PDPA, and Indonesian PDP electronic-systems certifications, and integrates with national health infrastructure including Singapore's SingPass and PRECISE program and Indonesia's SatuSehat platform via HL7-based APIs.

The company monetizes through one-time test kit sales, recurring Nala CDS software licensing, professional services for healthcare partners, and the 3-month NalaCare wellness subscription. It is headquartered in Singapore (1093 Lower Delta Road) with a regional office in Jakarta (PT Nalagenetik Riset Indonesia), operates across at least 12 countries, and has strategic relationships with government genomics programs (BGSi/BB Binomika Indonesia Ministry of Health, Singapore PRECISE), academic and clinical partners (NUH, NUS), and technology collaborators (Basepair for Nala Basecamp, Revna Biosciences for African expansion). The company has raised approximately US$13.6 million to date, anchored by a US$12.6 million Series A in March 2022 co-led by Intudo Ventures and Vulcan Capital, and is led by co-founder and CEO Levana Sani alongside co-founders Alexander Lezhava, Astrid Irwanto (COO), and Jianjun Liu.

Short descriptiontext

Nalagenetics is a Singapore-based genomics company founded in 2016 that delivers population-specific genetic testing products (pharmacogenomics, cancer risk, cardiovascular risk, nutrition, lifestyle) and an AI-powered Nala Clinical Decision Support platform to individual consumers, hospitals, labs, and government genomics programs across 12 countries in Southeast Asia and beyond.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBukit Merah, Singapore
HQ citystring
Bukit Merah
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
genetic testing services, pharmacogenomics solutions, clinical decision support, precision medicine platforms, polygenic risk scoring
Industry5 codes
PRIMARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLACAGAB
Medication Safety, Dosing & Drug Interaction CDS
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLACAKAH
Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT
SECONDARYHLAAANAC
Companion Diagnostics (CDx) Development & Commercialization
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Genomics & Clinical Decision Support Software
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Genetic Testing Products
TypeOne Time License
Description

One-time genetic testing services sold directly to consumers and healthcare providers. Products include pharmacogenomics tests (RxReady™, RxMax™), nutrigenetics (NutriReady™), lifestyle genomics (LifeReady™), cancer prevention (MammoReady™), and cardiovascular risk (CardiacReady™).

nalagenetics.com
2Clinical Decision Support Software Licensing
TypeSubscription Recurring
Description

Nala CDS platform licensed to healthcare institutions, labs, and research organizations for genomic analysis and reporting. Includes cloud-based and on-premise deployment options.

nalagenetics.com
3Healthcare Provider Services
TypeProfessional Services
Description

Professional services including training programs, sample collection logistics, genetic counseling, and clinical implementation support for healthcare partners.

nalagenetics.com
4NalaCare Wellness Program
TypeSubscription Recurring
Description

3-month personalized wellness programs combining genetic insights with clinical nutrition consultations, health analysis, and meal planning.

nalagenetics.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Pricing details1 tier
1Genetic test kits and analysis services
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Contact-based pricing; no public pricing listed on website. Customers directed to WhatsApp or email for quotes.

nalagenetics.com
GTM typeB2B and B2C
B2B and B2C
Offering typeSoftware
Software
Brand1 of 13 records shown
1NalaCare Clinic
Description

Healthcare clinic offering personalized counseling and preventive care services

nalagenetics.com
+12 more records
Core offering1 text field

Nalagenetics sells clinical-grade DNA test kits spanning pharmacogenomics, hereditary and somatic cancer, prenatal, rare disease, cardiovascular, nutrition, and lifestyle assessments, analyzed through its patented Nala Clinical Decision Support (CDS) software platform. The Nala CDS platform is licensed separately to hospitals, laboratories, and research institutions for cloud or on-premise genomic analysis deployment, while consumers can purchase tests directly online or through the NalaCare Clinic.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • Reduces serious side effects from medications by 30% when medications are matched to genetic profiles
+7 more records
Product overview1 text field

Nalagenetics is a genomics and precision medicine company offering a comprehensive portfolio of genetic testing products and a software platform for clinical decision support. The core offerings include pharmacogenomics tests (RxMax™ covering 240+ medications, RxReady™ covering 180+ medications), cancer risk prediction tests (MammoReady™ for breast cancer, Prevention of Cancer, Somatic Cancer Testing), cardiovascular risk assessment (CardiacReady™), nutrition and lifestyle genomics (NutriReady™, LifeReady™), prenatal testing, and rare disease diagnosis. These products are available as individual tests or bundled into health packages (Complete Wellness, Cardiovascular Prevention, Cancer Prevention, Medication Compatibility, Premarital Screening). The company also provides Nala CDS, an AI-powered clinical decision support platform for labs and researchers, and the Nala Personal Health Manager mobile app for patients to access their genetic reports. Products are designed specifically for Southeast Asian populations with localized algorithms and validation against diverse population data sets.

Product and service15 records
1RxMax™
CategoryPharmacogenomics DNA Test
Description

Pharmacogenomics test that analyzes a panel of 14 drug-gene pairs (including HLA-B*1502, HLA-B*5701, CYP2D6, CYP2C19, CYP2C9, SLCO1B1, VKORC1, DPYD, TPMT, UGT1A1, CYP3A5, CYP2B6, NUDT15, and CYP4F2) to provide personalized medication guidance for the top 100 most-prescribed drugs in Southeast Asia. Intended for consumers and clinicians concerned with drug response and adverse reactions.

2RxReady™
CategoryPharmacogenomics DNA Test
Description

Pharmacogenomics DNA test covering 8 drug-gene pairs for the top 50 most-prescribed drugs in Southeast Asia, providing medication compatibility insights and a personalized lifetime medication response card. Targeted at consumers seeking streamlined pharmacogenomic guidance.

3MammoReady™
CategoryHereditary Cancer Risk Test
Description

Genetic test assessing breast cancer risk via polygenic risk scoring combined with non-genetic risk factors. Designed for women seeking personalized breast cancer risk stratification to complement screening decisions.

4CardiacReady™
CategoryCardiovascular Risk Test
Description

Genetic test providing cardiovascular disease risk assessment using polygenic risk scoring combined with clinical and epigenetic markers. Intended for consumers concerned with heart disease risk and prevention.

5NutriReady™
CategoryNutrition DNA Test
Description

Nutrition-focused DNA test providing personalized dietary recommendations based on genetic predispositions. Targets consumers seeking genetically tailored nutrition guidance.

6LifeReady™
CategoryLifestyle DNA Test
Description

Lifestyle-focused DNA test covering predisposition to traits such as obesity, sleep patterns, and exercise response. Targeted at consumers interested in lifestyle optimization based on genetic profile.

7Prevention of Cancer (Hereditary Cancer Screening)
CategoryHereditary Cancer Screening
Description

Comprehensive hereditary cancer screening panel covering multiple cancer syndromes via microarray-based germline analysis. Designed for individuals with family history of cancer and clinicians managing high-risk patients.

8Somatic Cancer Testing
CategorySomatic Oncology Testing
Description

Tumor profiling test using microarray and next-generation sequencing for somatic cancer variant detection and interpretation. Intended for oncologists and cancer patients seeking tumor-level genomic insights.

9Prenatal (NIPT)
CategoryNon-Invasive Prenatal Testing
Description

Non-invasive prenatal testing (NIPT) using next-generation sequencing to screen for fetal chromosomal abnormalities. Targeted at expectant parents and obstetricians.

10Rare Disease Diagnosis
CategoryRare Disease Diagnostics
Description

Whole exome and whole genome sequencing-based diagnostic service for rare disease identification using microarray, NGS, and Optical Genome Mapping technologies. Targeted at clinicians and families seeking diagnoses for suspected rare genetic conditions.

11Nala Clinical Decision Support (CDS) Platform
CategoryClinical Decision Support Software
Description

Patented, AI-powered clinical decision support software platform for genomic analysis, available via cloud or on-premise deployment with HL7-based API integration to hospital information systems. Licensed to hospitals, clinics, and laboratories seeking clinical-grade genomic interpretation within routine care workflows.

12Nala Basecamp
CategoryNGS Analysis Software
Description

Next-generation sequencing analysis platform with one-click variant interpretation, distributed in partnership with Basepair for the global academic research community. Targeted at universities, research institutes, and biopharma R&D teams needing clinical-grade NGS tertiary analysis.

13Nala Personal Health Manager
CategoryConsumer Health Mobile App
Description

Mobile application available on iOS and Android for ordering genetic tests, accessing personal reports, and managing health insights on the go. Targeted at consumers who have purchased Nalagenetics tests.

14NalaCare Wellness Program
CategoryWellness Subscription Program
Description

3-month structured wellness program that combines genetic testing with three consultations by in-house doctors and certified genetic counselors, plus weekly lifestyle coaching and tracking. Delivered through the NalaCare Clinic in Singapore for consumers seeking guided personalized wellness journeys.

15Healthcare Provider Clinical Services
CategoryClinical Testing Services
Description

Clinical service offering for healthcare providers (specialists, physicians, genetic counselors) that combines genetic test ordering, sample logistics, result delivery, and patient report access through the Nalagenetics provider workflow. Targeted at clinical practitioners referring patients for genetic testing.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-01
Description

Partnership for DNA tests tailored to Africans. Revna Biosciences secured growth capital from Mirepa Capital to expand precision medicine capabilities, with active partnerships with AstraZeneca for biomarker testing and NalaGenetics for African-specific DNA tests.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

Strategic collaboration to launch Nala Basecamp, a collaborative platform integrating clinical genomics with advanced data analysis for pharmacogenomics and polygenic risk scores. Leverages cloud-native, regulatory-compliant bioinformatics.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

PRECISE-CIP project collaboration for pharmacogenomics clinical implementation pilot. NUH serves as the clinical site for the pilot program with 1,500 patients using Nala CDS for personalized treatment decisions.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

PRECISE-CIP project collaboration as part of Singapore's national precision medicine initiative. NUS provides research expertise and academic oversight for the pharmacogenomics clinical implementation pilot.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Singapore's national precision medicine initiative driving Phase II of the National Precision Medicine programme. Coordinates clinical implementation pilots and partnerships with genomics companies including Illumina, Oxford Nanopore Technologies, and PacBio.

6BGSi (Biomedical and Genome Science Institute)
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Indonesia's national precision medicine initiative led by BB Binomika of Ministry of Health. NalaGenetics provides pharmacogenomics bioinformatics pipeline for Indonesia's first 10K genomes project, deployed on AWS infrastructure with secure local data retention.

nalagenetics.com
7BB Binomika - Ministry of Health Indonesia
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Government research institute leading Indonesia's genomic biobanking and precision medicine initiative. NalaGenetics supports the 10K genomes project with PGx analysis pipeline integrated with AWS genome data infrastructure.

nalagenetics.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Asia-headquartered (Hong Kong) genetic testing and precision health company offering both DTC consumer tests and clinical genomics; closest direct peer given overlapping Asia regional focus, PGx and preventive genetic testing, and hybrid B2C/B2B model.

TypeDirect peer
Description

Clinical genetics testing platform serving healthcare providers, employers and population health programs with hereditary cancer, PGx and polygenic risk tests; directly comparable CDS-enabled, B2B-leaning model.

TypeDirect peer
Description

Clinical genetic testing company offering comprehensive hereditary cancer, PGx and rare disease testing to healthcare providers with enterprise software integrations; comparable across the clinical genomics portfolio and B2B sales motion.

TypeDirect peer
Description

Genomics platform powering population health and partner-branded DNA tests with a strong clinical decision support software layer; comparable operating model of platform-as-a-service + clinical reporting.

TypeBroad incumbent
Description

Largest DTC consumer genetic testing brand with growing therapeutics and PGx efforts; broad incumbent in the same product category, competing especially for health-conscious consumer wallet share.

TypeBroad incumbent
Description

Consumer genetic testing company with health and ancestry products, expanding into clinical and wellness segments; broad incumbent competing in DTC genetic testing globally.

TypeBroad incumbent
Description

Established clinical genomics company with hereditary cancer (BRCA), PGx and prenatal testing; broad incumbent offering overlapping clinical genomics products to healthcare providers.

TypeDirect peer
Description

DTC whole genome and exome sequencing company with consumer-facing reports covering health, wellness and pharmacogenomics; comparable product breadth across NIPT, rare disease and prevention.

9Genomic Prediction
TypeEmerging player
Description

Polygenic risk score focused company (initially embryo screening, expanding into disease risk); emerging player with overlapping polygenic risk scoring technology applied to clinical genomics.

TypeEmerging player
Description

Oncology-focused genomics company offering liquid biopsy and molecular diagnostics; emerging player overlapping with Nala's somatic cancer testing and population-scale genomics infrastructure.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nalagenetics

Genomics & Clinical Decision Support Softwarenalagenetics.com

Nalagenetics is a Singapore-based genomics company founded in 2016 that delivers population-specific genetic testing products (pharmacogenomics, cancer risk, cardiovascular risk, nutrition, lifestyle) and an AI-powered Nala Clinical Decision Support platform to individual consumers, hospitals, labs, and government genomics programs across 12 countries in Southeast Asia and beyond.

What Nalagenetics does

Nalagenetics is a Singapore-based genomics company founded in 2016 that develops genetic testing products and clinical decision support software, with a particular specialization in Southeast Asian population-specific algorithms. The company operates a dual business model spanning direct-to-consumer DNA test kits sold through its own e-commerce platform and NalaCare clinic (RxMax covering 240+ medications, RxReady covering 180+ medications, MammoReady for breast cancer risk, CardiacReady for cardiovascular risk, NutriReady for nutrition, LifeReady for lifestyle, plus prenatal and rare disease diagnostics) and a B2B enterprise platform called Nala CDS that delivers NGS data analysis, pharmacogenomics reporting, polygenic risk scoring, and combined genetics-plus-epigenetics risk assessment to hospitals, laboratories, and research institutions on cloud-based or on-premise deployment.

The underlying technology stack combines multiple genomic modalities — microarray, qPCR, whole-genome sequencing (WGS), whole-exome sequencing (WES), and optical genome mapping (OGM) — with proprietary AI-powered bioinformatics for pharmacogenomics interpretation, polygenic risk scoring across 10+ conditions, and ACMG-compliant rare disease pipelines. The platform holds ISO 13485, ISO 27001, HIPAA, Singapore PDPA, and Indonesian PDP electronic-systems certifications, and integrates with national health infrastructure including Singapore's SingPass and PRECISE program and Indonesia's SatuSehat platform via HL7-based APIs.

The company monetizes through one-time test kit sales, recurring Nala CDS software licensing, professional services for healthcare partners, and the 3-month NalaCare wellness subscription. It is headquartered in Singapore (1093 Lower Delta Road) with a regional office in Jakarta (PT Nalagenetik Riset Indonesia), operates across at least 12 countries, and has strategic relationships with government genomics programs (BGSi/BB Binomika Indonesia Ministry of Health, Singapore PRECISE), academic and clinical partners (NUH, NUS), and technology collaborators (Basepair for Nala Basecamp, Revna Biosciences for African expansion). The company has raised approximately US$13.6 million to date, anchored by a US$12.6 million Series A in March 2022 co-led by Intudo Ventures and Vulcan Capital, and is led by co-founder and CEO Levana Sani alongside co-founders Alexander Lezhava, Astrid Irwanto (COO), and Jianjun Liu.

Nalagenetics firmographics

Firmographics
Name
Nalagenetics
Legal name
Nalagenetics Pte Ltd
Website
https://nalagenetics.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Nalagenetics is a Singapore-based genomics company founded in 2016 that delivers population-specific genetic testing products (pharmacogenomics, cancer risk, cardiovascular risk, nutrition, lifestyle) and an AI-powered Nala Clinical Decision Support platform to individual consumers, hospitals, labs, and government genomics programs across 12 countries in Southeast Asia and beyond.
Ownership category
akta.pro rank

Nalagenetics industry classification

Industry
Product category
Genomics & Clinical Decision Support Software
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLACAGAB
Medication Safety, Dosing & Drug Interaction CDS
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLACAKAH
Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT
SECONDARYHLAAANAC
Companion Diagnostics (CDx) Development & Commercialization
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

  • Genetic testing services
  • Pharmacogenomics solutions
  • Clinical decision support
  • Precision medicine platforms
  • Polygenic risk scoring

Where Nalagenetics is headquartered

Location

Headquarters

HQ city
Bukit Merah
HQ country
Singapore
HQ region
Asia

Offices2 records

Markets served

Nalagenetics business model

Business model
GTM type
B2B and B2C
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Genetic Testing Products: One-time genetic testing services sold directly to consumers and healthcare providers. Products include pharmacogenomics tests (RxReady™, RxMax™), nutrigenetics (NutriReady™), lifestyle genomics (LifeReady™), cancer prevention (MammoReady™), and cardiovascular risk (CardiacReady™).
  2. Clinical Decision Support Software Licensing: Nala CDS platform licensed to healthcare institutions, labs, and research organizations for genomic analysis and reporting. Includes cloud-based and on-premise deployment options.
  3. Healthcare Provider Services: Professional services including training programs, sample collection logistics, genetic counseling, and clinical implementation support for healthcare partners.
  4. NalaCare Wellness Program: 3-month personalized wellness programs combining genetic insights with clinical nutrition consultations, health analysis, and meal planning.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goGenetic test kits and analysis services

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Nalagenetics product offering

Product offering

Core offering

Nalagenetics sells clinical-grade DNA test kits spanning pharmacogenomics, hereditary and somatic cancer, prenatal, rare disease, cardiovascular, nutrition, and lifestyle assessments, analyzed through its patented Nala Clinical Decision Support (CDS) software platform. The Nala CDS platform is licensed separately to hospitals, laboratories, and research institutions for cloud or on-premise genomic analysis deployment, while consumers can purchase tests directly online or through the NalaCare Clinic.

Product overview

Nalagenetics is a genomics and precision medicine company offering a comprehensive portfolio of genetic testing products and a software platform for clinical decision support. The core offerings include pharmacogenomics tests (RxMax™ covering 240+ medications, RxReady™ covering 180+ medications), cancer risk prediction tests (MammoReady™ for breast cancer, Prevention of Cancer, Somatic Cancer Testing), cardiovascular risk assessment (CardiacReady™), nutrition and lifestyle genomics (NutriReady™, LifeReady™), prenatal testing, and rare disease diagnosis. These products are available as individual tests or bundled into health packages (Complete Wellness, Cardiovascular Prevention, Cancer Prevention, Medication Compatibility, Premarital Screening). The company also provides Nala CDS, an AI-powered clinical decision support platform for labs and researchers, and the Nala Personal Health Manager mobile app for patients to access their genetic reports. Products are designed specifically for Southeast Asian populations with localized algorithms and validation against diverse population data sets.

Differentiator

Problem solved

Functional benefit

Brands

  • NalaCare Clinic: Healthcare clinic offering personalized counseling and preventive care services
  • Nala Clinical Decision Support (CDS)
  • Nala Personal Health Manager
  • NalaCare Program
  • Nala Basecamp
  • NutriReady
  • LifeReady
  • CardiacReady
  • MammoReady
  • RxMax
  • RxReady
  • QuickSpit
  • PGx Core

Products and services

  • RxMax™ Pharmacogenomics test that analyzes a panel of 14 drug-gene pairs (including HLA-B*1502, HLA-B*5701, CYP2D6, CYP2C19, CYP2C9, SLCO1B1, VKORC1, DPYD, TPMT, UGT1A1, CYP3A5, CYP2B6, NUDT15, and CYP4F2) to provide personalized medication guidance for the top 100 most-prescribed drugs in Southeast Asia. Intended for consumers and clinicians concerned with drug response and adverse reactions.
  • RxReady™ Pharmacogenomics DNA test covering 8 drug-gene pairs for the top 50 most-prescribed drugs in Southeast Asia, providing medication compatibility insights and a personalized lifetime medication response card. Targeted at consumers seeking streamlined pharmacogenomic guidance.
  • MammoReady™ Genetic test assessing breast cancer risk via polygenic risk scoring combined with non-genetic risk factors. Designed for women seeking personalized breast cancer risk stratification to complement screening decisions.
  • CardiacReady™ Genetic test providing cardiovascular disease risk assessment using polygenic risk scoring combined with clinical and epigenetic markers. Intended for consumers concerned with heart disease risk and prevention.
  • NutriReady™ Nutrition-focused DNA test providing personalized dietary recommendations based on genetic predispositions. Targets consumers seeking genetically tailored nutrition guidance.
  • LifeReady™ Lifestyle-focused DNA test covering predisposition to traits such as obesity, sleep patterns, and exercise response. Targeted at consumers interested in lifestyle optimization based on genetic profile.
  • Prevention of Cancer (Hereditary Cancer Screening) Comprehensive hereditary cancer screening panel covering multiple cancer syndromes via microarray-based germline analysis. Designed for individuals with family history of cancer and clinicians managing high-risk patients.
  • Somatic Cancer Testing Tumor profiling test using microarray and next-generation sequencing for somatic cancer variant detection and interpretation. Intended for oncologists and cancer patients seeking tumor-level genomic insights.
  • Prenatal (NIPT) Non-invasive prenatal testing (NIPT) using next-generation sequencing to screen for fetal chromosomal abnormalities. Targeted at expectant parents and obstetricians.
  • Rare Disease Diagnosis Whole exome and whole genome sequencing-based diagnostic service for rare disease identification using microarray, NGS, and Optical Genome Mapping technologies. Targeted at clinicians and families seeking diagnoses for suspected rare genetic conditions.
  • Nala Clinical Decision Support (CDS) Platform Patented, AI-powered clinical decision support software platform for genomic analysis, available via cloud or on-premise deployment with HL7-based API integration to hospital information systems. Licensed to hospitals, clinics, and laboratories seeking clinical-grade genomic interpretation within routine care workflows.
  • Nala Basecamp Next-generation sequencing analysis platform with one-click variant interpretation, distributed in partnership with Basepair for the global academic research community. Targeted at universities, research institutes, and biopharma R&D teams needing clinical-grade NGS tertiary analysis.
  • Nala Personal Health Manager Mobile application available on iOS and Android for ordering genetic tests, accessing personal reports, and managing health insights on the go. Targeted at consumers who have purchased Nalagenetics tests.
  • NalaCare Wellness Program 3-month structured wellness program that combines genetic testing with three consultations by in-house doctors and certified genetic counselors, plus weekly lifestyle coaching and tracking. Delivered through the NalaCare Clinic in Singapore for consumers seeking guided personalized wellness journeys.
  • Healthcare Provider Clinical Services Clinical service offering for healthcare providers (specialists, physicians, genetic counselors) that combines genetic test ordering, sample logistics, result delivery, and patient report access through the Nalagenetics provider workflow. Targeted at clinical practitioners referring patients for genetic testing.

Quantifiable outcome

  • Reduces serious side effects from medications by 30% when medications are matched to genetic profiles
  • +7 more outcomes

Companies that use Nalagenetics

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Nalagenetics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability4 records

Feature7 records

Nalagenetics partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and flagship.

  • Revna BiosciencescoreStrategic or Co-development Partner · 1 March 2026Partnership for DNA tests tailored to Africans. Revna Biosciences secured growth capital from Mirepa Capital to expand precision medicine capabilities, with active partnerships with AstraZeneca for biomarker testing and NalaGenetics for African-specific DNA tests.
  • BasepaircoreStrategic or Co-development Partner · 1 October 2025Strategic collaboration to launch Nala Basecamp, a collaborative platform integrating clinical genomics with advanced data analysis for pharmacogenomics and polygenic risk scores. Leverages cloud-native, regulatory-compliant bioinformatics.
  • National University Hospital (NUH)coreStrategic or Co-development PartnerPRECISE-CIP project collaboration for pharmacogenomics clinical implementation pilot. NUH serves as the clinical site for the pilot program with 1,500 patients using Nala CDS for personalized treatment decisions.
  • National University of Singapore (NUS)coreStrategic or Co-development PartnerPRECISE-CIP project collaboration as part of Singapore's national precision medicine initiative. NUS provides research expertise and academic oversight for the pharmacogenomics clinical implementation pilot.
  • Precision Health Research, Singapore (PRECISE)coreStrategic or Co-development PartnerSingapore's national precision medicine initiative driving Phase II of the National Precision Medicine programme. Coordinates clinical implementation pilots and partnerships with genomics companies including Illumina, Oxford Nanopore Technologies, and PacBio.
  • BGSi (Biomedical and Genome Science Institute)flagshipStrategic or Co-development PartnerIndonesia's national precision medicine initiative led by BB Binomika of Ministry of Health. NalaGenetics provides pharmacogenomics bioinformatics pipeline for Indonesia's first 10K genomes project, deployed on AWS infrastructure with secure local data retention.
  • BB Binomika - Ministry of Health IndonesiaflagshipStrategic or Co-development PartnerGovernment research institute leading Indonesia's genomic biobanking and precision medicine initiative. NalaGenetics supports the 10K genomes project with PGx analysis pipeline integrated with AWS genome data infrastructure.

Scale indicators6 records

Recent moves6 records

Expansion highlights7 records

Nalagenetics competitors and assessment

Company assessment

Direct peers

  • Prenetics: Asia-headquartered (Hong Kong) genetic testing and precision health company offering both DTC consumer tests and clinical genomics; closest direct peer given overlapping Asia regional focus, PGx and preventive genetic testing, and hybrid B2C/B2B model.
  • Color Health: Clinical genetics testing platform serving healthcare providers, employers and population health programs with hereditary cancer, PGx and polygenic risk tests; directly comparable CDS-enabled, B2B-leaning model.
  • Invitae: Clinical genetic testing company offering comprehensive hereditary cancer, PGx and rare disease testing to healthcare providers with enterprise software integrations; comparable across the clinical genomics portfolio and B2B sales motion.
  • Helix: Genomics platform powering population health and partner-branded DNA tests with a strong clinical decision support software layer; comparable operating model of platform-as-a-service + clinical reporting.
  • Dante Labs: DTC whole genome and exome sequencing company with consumer-facing reports covering health, wellness and pharmacogenomics; comparable product breadth across NIPT, rare disease and prevention.

Broad incumbents

  • 23andMe: Largest DTC consumer genetic testing brand with growing therapeutics and PGx efforts; broad incumbent in the same product category, competing especially for health-conscious consumer wallet share.
  • MyHeritage: Consumer genetic testing company with health and ancestry products, expanding into clinical and wellness segments; broad incumbent competing in DTC genetic testing globally.
  • Myriad Genetics: Established clinical genomics company with hereditary cancer (BRCA), PGx and prenatal testing; broad incumbent offering overlapping clinical genomics products to healthcare providers.

Emerging players

  • Genomic Prediction: Polygenic risk score focused company (initially embryo screening, expanding into disease risk); emerging player with overlapping polygenic risk scoring technology applied to clinical genomics.
  • Guardant Health: Oncology-focused genomics company offering liquid biopsy and molecular diagnostics; emerging player overlapping with Nala's somatic cancer testing and population-scale genomics infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Nalagenetics social profiles

Digital presence

Nalagenetics compliance and trust

Trust signal

Compliance6 records

Nalagenetics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nalagenetics leadership team

Management profile

Number of profiles

Profiles4 records

Nalagenetics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Nalagenetics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nalagenetics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nalagenetics

What does Nalagenetics do?

Nalagenetics sells clinical-grade DNA test kits spanning pharmacogenomics, hereditary and somatic cancer, prenatal, rare disease, cardiovascular, nutrition, and lifestyle assessments, analyzed through its patented Nala Clinical Decision Support (CDS) software platform. The Nala CDS platform is licensed separately to hospitals, laboratories, and research institutions for cloud or on-premise genomic analysis deployment, while consumers can purchase tests directly online or through the NalaCare Clinic.

Is Nalagenetics a public or private company?

Nalagenetics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Nalagenetics founded?

Nalagenetics was founded in 2016. It employs 11 to 50 people.

Where is Nalagenetics based?

Nalagenetics is headquartered in Bukit Merah, Singapore, in the Asia region.

How does Nalagenetics make money?

Four revenue lines are on record. Genetic Testing Products are the primary driver. The others are clinical Decision Support Software Licensing, healthcare Provider Services and nalaCare Wellness Program.

Who are Nalagenetics's main competitors?

Direct peers on record are Prenetics, Color Health, Invitae, Helix and Dante Labs. Broad incumbents are 23andMe, MyHeritage and Myriad Genetics. Emerging players are Genomic Prediction and Guardant Health.

Does Nalagenetics have an API?

No public API is recorded for Nalagenetics.

What industry is Nalagenetics in?

Nalagenetics's product category is Genomics & Clinical Decision Support Software. Its primary akta.pro industry code is HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics), with a secondary code of HLACAGAB, Medication Safety, Dosing & Drug Interaction CDS. Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireBasepair and NalaGenetics Form Strategic Collaboration to Launch Next Generation Clinical Genomics PlatformBasepair and NalaGenetics announced a strategic collaboration to launch Basecamp, a clinical genomics platform integrating bioinformatics and genetic testing modules. The platform aims to accelerate precision medicine adoption globally, with pilot projects underway in Europe and Asia-Pacific.NatureThree science-led start-ups making their markNature Index profiles three science-led start-ups that originated from university research: Twelve, a California-based carbon-conversion company that has raised $645 million to build its first commercial-scale plant (AirPlant) in Moses Lake, Washington; Riverkin, a Swiss start-up founded in 2024 that is developing river sensors to help hydropower operators protect turbines from sediment damage; and NalaGenetics, a healthcare-focused start-up founded by university researchers. Twelve, co-founded by a Stanford PhD graduate, has attracted collaborations with major companies including Microsoft, Procter & Gamble, and Mercedes-Benz, and is preparing to produce sustainable aviation fuel using its CO2-conversion technology.LinkedInNalaGenetics posted on LinkedInNalaGenetics announced the completion of its Series A fundraise, expressing gratitude to investors and partners for their support. The company aims to expand its genomics analysis software for diverse populations and is actively recruiting for senior roles in business development, marketing, product management, bioinformatics, IT, and engineering.PR NewswireNalagenetics obtient le marquage CE pour son logiciel de pharmacogénomique, Nala Clinical Decision Support™ Module- PGx CoreNalagenetics, a Singapore-based genomics company, has obtained CE marking for its Nala Clinical Decision Support™ Module - PGx Core software, enabling commercialization of the pharmacogenomic tool across Europe and clearing a pathway for regulatory approval in Southeast Asia. The software, paired with the Nala PGx Core® qPCR kit, detects 20 variants across four pharmacogenes and generates over 170 drug-gene interaction reports, addressing adverse drug reactions which cause 8% of hospital admissions in Singapore and rank as the fourth leading cause of death in the United States. CEO Levana Sani stated the certification establishes credibility in the European market as pharmacogenomic testing adoption accelerates globally.PR Newswire APACNalagenetics obtains CE Mark for its pharmacogenomics software, Nala Clinical Decision Support™ Module- PGx CoreNalagenetics completed CE-marking for its Nala Clinical Decision Support Module-PGx Core, enabling European marketing and Southeast Asian expansion. The software pairs with its qPCR kit to generate drug-gene reports for pharmacogenomics. The company aims to build credibility in Europe and Southeast Asia.PR NewswireNalagenetics obtiene la Marca CE por su software de farmacogenómicaNalagenetics, a Singapore-based genetic testing company, has obtained CE marking for its Nala Clinical Decision Support™ Module- PGx Core software, enabling the company to market the product across Europe and supporting further approval in Southeast Asia. The software accompanies the Nala PGx Core® qPCR kit, which genotypes 20 variants across four pharmacogenes and can generate over 170 medication gene reports to support personalized prescribing. CEO Levana Sani stated the milestone provides credibility in the European and Southeast Asian markets as pharmacogenomic testing adoption grows globally.PR NewswireNalagenetics erhält CE-Kennzeichnung für seine Pharmakogenomik-Software, Nala Clinical Decision Support™ Module- PGx CoreNalagenetics Pte Ltd has received CE marking for its Nala Clinical Decision Support™ Module - PGx Core pharmacogenomics software, enabling marketing in Europe and supporting regulatory approval in Southeast Asia. The module is companion software for the Nala PGx Core® qPCR kit, which genotypes 20 variants across four key pharmacogenes and can generate over 170 drug-gene reports. CEO Levana Sani stated this milestone strengthens the company's credibility in European and Southeast Asian markets as pharmacogenomic testing adoption grows globally.PR Newswire APACMGI announces partnership with Nalagenetics to advance pharmacogenomics in Singapore and IndonesiaMGI and Nalagenetics announced a partnership to co-develop low-coverage whole genome sequencing for pharmacogenomics, using MGI's DNBSEQ platform and Nalagenetics' Clinical Decision Support software. The collaboration aims to simplify NGS workflows and generate clinical-grade reports for risk prediction in Southeast Asia.AsiaTechDailyNalagenetics secures $12.6m in funding to boost genetic testing solutionsNalagenetics has successfully closed a Series A funding round totaling US$12.6 million, co-led by Intudo Ventures and Vulcan Capital, to enhance its genetic testing solutions. This funding will also be used to focus on product development and increase staff in bioinformatics, software engineering, and genetics as they aim to advance cost-effective genetic screening in Southeast Asia.